Genmab A/S (ETR:GE9)

Market Cap	15.24B
Revenue (ttm)	3.28B
Net Income (ttm)	1.35B
Shares Out	n/a
EPS (ttm)	21.39
PE Ratio	11.29
Forward PE	15.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	182
Open	247.60
Previous Close	246.30
Day's Range	246.00 - 247.60
52-Week Range	233.20 - 284.50
Beta	n/a
RSI	38.40
Earnings Date	Nov 6, 2025

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 2,682
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GE9

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD